Vancomycin: The tale of the vanquisher and the pyrrhic victory

Peritoneal Dialysis International

Volumn 34, Issue 2, 2014, Pages 154-161

[No Author Info available]

Author keywords

MRSA; Vancomycin; VISA

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DOSE RESPONSE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GROWTH INHIBITION; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; NONHUMAN; PERITONITIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STAPHYLOCOCCAL BACTEREMIA; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; DRUG EFFECTS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84924106688     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2014.00001     Document Type: Review

References (54)

1. Vandecasteele SJ, Boelaert JR, De Vriese AS. Staphylococ­cus aureus infections in hemodialysis: what a nephrologist should know. Clin J Am Soc Nephrol 2009;4:1388–400.
2. Lowy FD. Antimicrobial resistance: the example of Staphy­lococcus aureus. J Clin Invest 2003; 111:1265–73.
3. Cosgrove SE, Carroll KC, Perl TM. Staphylococcus aureus with reduced susceptibility to vancomycin. Clin Infect Dis 2004; 39:539–45.
4. Vandecasteele SJ, De Vriese AS, Tacconelli E. The phar­macokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties. J Antimicrob Chemother 2013; 68:743–8.
5. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphy­lococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother2004; 48:4665–72.
6. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al.Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm2009; 66:82–98. [Erratum in: Am J Health Syst Pharm 2009; 66:887]
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimi­crob Chemother1997; 40:135–6.
8. Howden BP, Peleg AY, Stinear TP. The evolution of van­comycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. Infect Genet Evol 2013; S1567-1348(13)00136-6.
9. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycinminimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208–15.
10. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol 2004; 42:2398–402.
11. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, et al.Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphy­lococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother2009; 53:4127–32.
12. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. Predict­ing high vancomycin minimum inhibitory concentration in methicillin resistant Staphylococcus aureus bloodstream infections. Clin Infect Dis 2011; 52:997–1002.
13. Kehrmann J, Kaase M, Szabados F, Gatermann SG, Buer J, Rath PM, et al.Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur J Clin Microbiol Infect Dis 2011; 30:677–83.
14. Centers for Disease Control and Prevention. Staphylococ­cus aureus resistant to vancomycin—United States, 2002. MMWRMorb Mortal Wkly Rep 2002; 51:565–7.
15. Gould IM. VRSA-doomsday superbug or damp squib? Lancet Infect Dis 2010; 10:816–18.
16. Moravvej Z, Estaji F, Askari E, Solhjou K, Naderi Nasab M, Saadat S. Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains. Int J Antimicrob Agents 2013; 42:370–1.
17. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis 2004; 38:448–51.
18. Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, et al.Comparison of the clinical features, bacterial geno­types and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J Antimicrob Chemother 2012; 67:1843–9.
19. van Hal SJ, Lodise TP, Paterson DL. The clinical signifi­cance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755–71.
20. Sakoulas G, Eliopoulos GM, Moellering RC Jr, Novick RP, Venkataraman L, Wennersten C, et al. Staphylococ­cus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermedi­ate-level glycopeptide resistance? J Infect Dis 2003; 187:929–38.
21. Sakoulas G, Eliopoulos GM, Fowler VG Jr, Moellering RC Jr, Novick RP, Lucindo N, et al.Reduced susceptibility of Staphylococcus aureus to vancomycin and platelet micro­bicidal protein correlates with defective autolysis and loss of accessory gene regulator (agr) function. Antimicrob Agents Chemother2005; 49:2687–92.
22. Liu C, Chambers HF. Staphylococcus aureus with heteroge­neous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic meth­ods. Antimicrob Agents Chemother2003; 47:3040–5.
23. van Hal SJ, Steen JA, Espedido BA, Grimmond SM, Cooper MA, Holden MT, et al. In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient iso­lates: the entire picture or a cautionary tale? J Antimicrob Chemother 2014; 69:363–7.
24. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vanco­mycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975–81.
25. van Hal SJ, Paterson DL, Lodise TP. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 57:734–44.
26. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N. Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother2012; 67:17–24.
27. Cano EL, Haque NZ, Welch VL, Cely CM, Peyrani P, Scerpella EG, et al. on behalf of the Improving Medicine through Pathway Assessment of Critical Therapy of Hospital-Acquired Pneumonia (IMPACT-HAP) Study Group. Inci­dence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: ret­rospective analysis of the IMPACT-HAP database. Clin Ther 2012; 34:149–57.
28. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507–14.
29. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al.Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 54:621–9.
30. Vandecasteele SJ, De Vriese AS. Recent changes in van­comycin use in renal failure. Kidney Int 2010; 77:760–4.
31. Vandecasteele SJ, De Vriese AS. Vancomycin dosing in patients on intermittent hemodialysis. Semin Dial 2011; 24:50–5.
32. Pallotta KE, Manley HJ. Vancomycin use in patients requir­ing hemodialysis: a literature review. Semin Dial 2008; 21:63–70.
33. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50:929–36.
34. Ariano RE, Fine A, Sitar DS, Rexrode S, Zelenitsky SA. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. Am J Kidney Dis 2005; 46:681–7.
35. Pai AB, Pai MP. Vancomycin dosing in high flux hemodialy­sis: a limited-sampling algorithm. Am J Health Syst Pharm2004; 61:1812–16.
36. Vandecasteele SJ, De Bacquer D, De Vriese AS. Imple­mentation of a dose calculator for vancomycin to achieve target trough levels of 15–20 microg/mL in persons undergoing hemodialysis. Clin Infect Dis 2011; 53:124–9.
37. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. on behalf of the International Society for Peritoneal Dialysis. Peritoneal dialysis–related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393–423. [Erratum in: Perit Dial Int 2011; 31:512]
38. Schaefer F, Klaus G, Müller-Wiefel DE, Mehls O. Intermit­tent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dial­ysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). J Am Soc Nephrol 1999; 10:136–45.
39. Boyce NW, Wood C, Thomson NM, Kerr P, Atkins RC. Intraperitoneal (IP) vancomycin therapy for CAPD peritonitis—a prospective, randomized comparison of intermittent v continuous therapy. Am J Kidney Dis 1988; 12:304–6.
40. Szeto CC, Chow KM, Kwan BC, Law MC, Chung KY, Yu S, et al.Staphylococcus aureus peritonitis complicates peritoneal dialysis: review of 245 consecutive cases. Clin J Am Soc Nephrol 2007; 2:245–51.
41. Mulhern JG, Braden GL, O’Shea MH, Madden RL, Lipkowitz GS, Germain MJ. Trough serum vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. Am J Kidney Dis 1995; 25:611–15.
42. Pancorbo S, Comty C. Peritoneal transport of vancomycin in 4 patients undergoing continuous ambulatory perito­neal dialysis. Nephron 1982; 31:37–9.
43. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Vanco­mycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1983; 34:631–7.
44. Rogge MC, Johnson CA, Zimmerman SW, Welling PG. Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of perito­neal drug transport. Antimicrob Agents Chemother1985; 27:578–82.
45. Morse GD, Farolino DF, Apicella MA, Walshe JJ. Compara­tive study of intraperitoneal and intravenous vancomy­cin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother1987; 31:173–7.
46. Bastani B, Spyker DA, Westervelt FB Jr. Peritoneal absorption of vancomycin during and after resolution of peritonitis in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1988; 8:135–136.
47. Neal D, Bailie GR. Clearance from dialysate and equili­bration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 1990; 18:485–90.
48. Bailie GR, Eisele G, Venezia RA, Yocum D, Hollister A. Prediction of serum vancomycin concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal dialysis patients with peritonitis. Clin Pharma­cokinet 1992; 22:298–307.
49. Blowey DL, Warady BA, Abdel-Rahman S, Frye RF, Manley HJ. Vancomycin disposition following intraperitoneal administration in children receiving peritoneal dialysis. Perit Dial Int 2007; 27:79–85.
50. Montañés Pauls B, Almiñana MA, Casabó Alós VG. Vanco­mycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis. Eur J Pharm Sci 2011; 43:212–16.
51. Manley HJ, Bailie GR, Frye RF, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 2001; 21:378–85.
52. Blunden M, Zeitlin D, Ashman N, Fan SL. Single UK centre experience on the treatment of PD peritonitis—antibi­otic levels and outcomes. Nephrol Dial Transplant 2007; 22:1714–19.
53. de Vin F, Rutherford P, Faict D. Intraperitoneal administra­tion of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 2009; 29:5–15.
54. Hermsen ED, Hovde LB, Hotchkiss JR, Rotschafer JC. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003; 47:3764–7.